secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0001549595-23-000046
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Q3 FY2023 revenue $18.5M, net loss $37.0M; Seagen collaboration yields $60M upfront
--------------------------------------------------------------------------------

- Revenue of $18.5M, up 71% YoY, driven by $8M in research milestones from Gilead and Sanofi.
- Net loss of $37.0M ($0.68 per share) narrowed from $45.7M ($0.90) YoY.
- Cash, equivalents and marketable securities $268.7M as of Aug 31, 2023; runway into Q2 2025.
- Strategic collaboration with Seagen: $60M upfront, potential $3.4B milestones, option for U.S. profit sharing on two DAC products.
- Expects initial clinical data from NX-5948, NX-2127, and NX-1607 Phase 1 trials in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000046/0001549595-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000046/nrix-20231012.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer